Skip to content

Clinical trials

Mesothelioma, Malignant trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mesothelioma, Malignant Country / region: France Clear all

28 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20072
20101
20121
20132
20154
20162
20171
20181
20193
20201
20211
20223
20231
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Recruiting5
Terminated5
Unknown status4
Active, not recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
European Organisation for Research and Treatment of Cancer - EORTC2
Intergroupe Francophone de Cancerologie Thoracique2
University Hospital, Lille2
AGC Biologics S.p.A.1
Assistance Publique Hopitaux De Marseille1
AstraZeneca1
Centre Hospitalier Intercommunal Creteil1
Centre Oscar Lambret1
Checkpoint Therapeutics, Inc.1
European Lung Cancer Working Party1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mesothelioma, Malignant28
Carcinoma, Non-Small-Cell Lung5
Mesothelioma4
Colorectal Neoplasms3
Carcinoma, Bronchogenic2
Carcinoma, Hepatocellular2
Carcinoma, Renal Cell2
Carcinoma, Transitional Cell2
Endometrial Neoplasms2
Lung Neoplasms2

Trials

Showing 76 to 28 of 28. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.